Scientific publications 2011

Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa by Olliaro P, Djimdé A, Dorsey G, Karema C, Mårtensson A, Ndiaye JL, Sirima SB, Vaillant M, Zwang J. Am J Trop Med Hyg. 2011 Oct;85(4):619-25.
Click here to read the article

Novel 3-Nitro-1H-1,2,4-triazole-based Aliphatic and Aromatic Amines as anti-Chagasic Agents by Papadopoulou MV, Bourdin B, Bloomer WD, McKenzie C ,  Wilkinson SR, Prasittichai C, Brun R, Kaiser M, Torreele E. Journal of Medicinal Chemistry, Online, October 24, 2011
Click here to read the article

Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges by Chang S and Ioset JR. Future Medicinal Chemistry, September 2011, Volume 3, Number 11
Click here to read the article in PDF


Synthesis of 2H- and 14C-labeled fexinidazole and its primary metabolites labeled with 2H by Fontana E, Pignatti A, Venegoni S, and Bray MA. The Journal of labelled compounds and radiopharmaceuticals. August 30, 2011. DOI: 10.1002/jlcr.1914
Click here to read the article


Pediatric HIV - A Neglected Disease ? by Lallemant M, Chang S, Cohen R, and Pécoul R. The New English Journal of Medicine. 2011 August. 365:581-583.
Click here to read the article / PDF

Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal by Brasseur P, Badiane M, Cisse M, Agnamey P, Vaillant MT, Olliaro PL.  Malaria J. 2011 Jul 25;10:203.
Click here to read the article

Kinetoplastid Parasites by Von Geldern T, Harhay MO, Scandale I and Don R. Top Med Chem. DOI: 10.1007/7355_2011_17
Click here to read the article

SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis by Jacobs R.T, Nare B, Wring S.A, Orr M.D, Chen D, Sligar J.M, Jenks M.X, Noe R.A, Bowling T.S, Mercer L.T, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi C.J, Yarlett N, Plattner J.J, Freund Y, Ding C, Akama T, Zhang Y-K, Brun R, Kaiser M, Scandale I, Don R. PLoS NTD. 2011 June. e1151. doi:10.1371/journal.pntd.0001151
Click here to read the article  / PDF


Potential Drug Development Candidates for Human Soil-Transmitted Helminthiases by Olliaro P, Seiler J, Kuesel A, Horton J, Clark J.N, Don R, Keiser J. PLoS NTD. 2011 June. 5(6): e1138.
Click here to read the article


Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo by Tong J, Valverde O, Mahoudeau C, Yun O, Chappuis F. Conflict and Health. May 2011, 5:7 doi:10.1186/1752-1505-5-7
Click here to read the article


Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience by Bompart F, Kiechel J-R, Sebbag R, Pecoul B. Malaria Journal. May 2011, 10:143doi:10.1186/1475-2875-10-143
Click here to read the article


The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership by Lacaze C, Kauss T, Kiechel J-R, Caminiti A, Fawaz F, Terrassin L, Cuart S, Grislain L, Navaratnam V, Ghezzoul B, Gaudin K, White N.J, Olliaro P, Millet P. Malaria Journal. May 2011, 10:142doi:10.1186/1475-2875-10-142
Click here to read the article


Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under five. by Olliaro P, Djimdé A, Karema C, Mårtensson A, Ndiaye JL, Sirima SB, Dorsey G, Zwang J. Tropical Medicine & International Health. May 2011. 16(5):551-4. doi: 10.1111/j.1365-3156.2011.02738.x
Click here to read the article


Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia by Harhay M.o, Olliaro P.L, Vaillant M, Chappuis F, Lima M.A, Ritmeijer K, Costa C.H, Costa D.L, Rijal S, Sundar S, Balasegaram M. Am. J. Trop. Med. Hyg. 84(4), 2011, pp. 543–550, doi:10.4269/ajtmh.2011.10-0321
Click here to access the article


Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand by S. Krudsood1, S. Looareesuwan, P. Wilairatama, W. Leowattana, N. Tangpukdee, K. Chalermrut, S. Ramanathan, V. Navaratnam, P. Olliaro, M. Vaillant, J. R. Kiechel, W. R. J. Taylor. Tropical Medicine & International Health. Volume 16, Issue 4, pages 458–465 , April 2011
Click here to access the article


Drug discovery and development for neglected diseases: the DNDi model by Chatelain E and Ioset J-R. Drug Design, Development and Therapy, 2011 March, Vol. 5, 175-181.
Click here to read the article


1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis
by Bourdin Trunz B, Jędrysiak R, Tweats D, Brun R, Kaiser M, Suwiński J and Torreele E. European Journal of Medicinal Chemistry, available online 5 February 2011, doi: 10.1016/j.ejmech.2011.01.071
Nitroimidazoles are a well-known class of antibacterial and antiprotozoal drugs but in spite of the widespread clinical and veterinary use of these drugs, this family has been stigmatized in part due to associated genotoxicity problems. Here we report the synthesis, the anti-trypanosomal activity and a structure–activity relationship (SAR) study of a series of about fifty 1-aryl-4-nitro-1H-imidazoles, with an emphasis on selected in vivo active molecules. Compounds 4-nitro-1-{4-(trifluoromethoxy)phenyl}-1H-imidazole and 1-(3,4-dichlorophenyl)-4-nitro-1H-imidazole are promising leads for the treatment of human African trypanosomiasis (HAT or sleeping sickness), including the fatal stage 2 of the disease, for which new treatments are urgently needed.
Click here to read the article


Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi by Amuasi JH, Diap G, Blay-Nguah S, Boakye I, Karikari PE, Dismas B, Karenzo J, Nsabiyumva L, Louie KS, Kiechel J. Malaria Journal 2011, 10:34 (10 February 2011) doi:10.1186/1475-2875-10-34
Conclusions: AS-AQ was widely available and affordable in the public and NGO markets of hard-to-reach post-conflict communities in Burundi. However greater accessibility and affordability of policy recommended anti-malarials in the private market sector is needed to improve country-wide policy uptake.
Click here to read the article / PDF

Registering New Drugs for Low-Income Countries: The African Challenge by Moran M, Strub-Wourgaft N, Guzman J, Boulet P, Wu L, Pecoul B. PLoS Medicine, 2011 February, Vol. 8, Issue 2, e1000411.
Click here to read the article / PDF
More about the Regulatory process in the African context here

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial by Sundar S, Sinha P.K, Rai M, Verma D.K, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal C.S, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Lancet, 2011 January, DOI:10.1016/S0140-6736(10)62050-8.
Click here to read the article / PDF

Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand by Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel J-R, Taylor V.R.J. Tropical Medicine and International Health, 2011 January, doi:10.1111/j.1365-3156.2010.02714.x.
Click here to read the article